Risk for ER-positive, HER2-negative breast cancers depends on biomarkers like tumor grade, estrogen receptor expression robustness, and genomic tests such as the Oncotype DX Recurrence Score.

“within this large group of er positive her2 negative cancers the risk uh depends on some of these biomarkers like grade so low grade intermediate grade higher grade um how robust the expression of the estrogen receptor is and nowadays we also use so-called genomic tests like the unyp DX recurrence score to understand for that large group of cancers how risky they are and whether they warrant chemotherapy”